Medicamen Biotech Financial Results
- Market cap
- ₹413 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹219.46 – ₹411.48
In the Q1 quarter, Medicamen Biotech reported revenue of ₹33.07 crore, and net profit of ₹3.72 crore. The operating margin was 19%. Earnings per share were ₹13.55.
Summary
Medicamen Biotech Limited is showing strong operational fundamentals with healthy volume activity and bullish technical indicators.
AI-generated summary of public data — not investment advice · 9 October 2026
Medicamen Biotech quarterly results
Consolidated figures, newest quarter first.
| Item | Q1 |
|---|---|
| Revenue | 33.07 |
| Expenses | 26.87 |
| Operating profit | 6.2 |
| Operating margin % | 19% |
| Other income | 45 |
| Interest | 12 |
| Depreciation | 35 |
| Profit before tax | 4.96 |
| Tax % | 25% |
| Net profit | 3.72 |
| EPS (₹) | 13.55 |
Medicamen Biotech annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | FY25 |
|---|---|
| Revenue | 145 |
| Expenses | 116 |
| Operating profit | 28.94 |
| Operating margin % | 20% |
| Other income | 180 |
| Interest | 50 |
| Depreciation | 140 |
| Profit before tax | 22.74 |
| Tax % | 25% |
| Net profit | 16.95 |
| EPS (₹) | 54.19 |
| Dividend payout % | 22% |
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Medicamen Biotech financial results — frequently asked questions
What were Medicamen Biotech's latest quarterly results?
For the Q1 quarter (consolidated), Medicamen Biotech reported revenue of ₹33.07 crore, operating profit of ₹6.2 crore and net profit of ₹3.72 crore, with EPS of ₹13.55.
What is Medicamen Biotech's annual revenue and net profit?
For the financial year ended FY25, Medicamen Biotech's revenue was ₹145 crore and net profit ₹16.95 crore.
What is the EPS of Medicamen Biotech?
Quarterly EPS for Q1 was ₹13.55. Annual EPS for FY25 was ₹54.19.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Medicamen Biotech With ATS
Track MEDICAMEQ live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.